$74,725,667

Latest obligation on CDC's traveler-based genomic surveillance program, which began in February 2025 to monitor pathogen variants in international travelers.

Genomic surveillance of incoming travelers provides early warning of emerging disease variants, critical for pandemic preparedness and public health response.

Ginkgo Bioworks' synthetic biology and sequencing capabilities position it as a key vendor in U.S. biosecurity infrastructure for pathogen detection.

U.S. investment in domestic genomic surveillance capacity reduces reliance on foreign sequencing and bioanalysis capabilities amid biotech competition.